Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis.
about
Mechanisms of sodium channel clustering and its influence on axonal impulse conductionB Cells and Autoantibodies in Multiple SclerosisNode of Ranvier disruption as a cause of neurological diseasesMolecular mechanisms of acrolein-mediated myelin destruction in CNS trauma and diseaseDisruption of axo-glial junctions causes cytoskeletal disorganization and degeneration of Purkinje neuron axonsElectron tomography of paranodal septate-like junctions and the associated axonal and glial cytoskeletons in the central nervous system.Sodium channel Nav1.6 accumulates at the site of infraorbital nerve injury.Axonal Membranes and Their Domains: Assembly and Function of the Axon Initial Segment and Node of Ranvier.Novel forms of neurofascin 155 in the central nervous system: alterations in paranodal disruption models and multiple sclerosisMyelination and regional domain differentiation of the axon.Spatiotemporal ablation of myelinating glia-specific neurofascin (Nfasc NF155) in mice reveals gradual loss of paranodal axoglial junctions and concomitant disorganization of axonal domains.Organization and maintenance of molecular domains in myelinated axonsMyelin recovery in multiple sclerosis: the challenge of remyelinationNodes of ranvier and paranodes in chronic acquired neuropathiesA phenotypic culture system for the molecular analysis of CNS myelination in the spinal cord.Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosisParanodal myelin retraction in relapsing experimental autoimmune encephalomyelitis visualized by coherent anti-Stokes Raman scattering microscopyAge-related molecular reorganization at the node of RanvierParanodal reorganization results in the depletion of transverse bands in the aged central nervous system.Neurofascin as a novel target for autoantibody-mediated axonal injuryAcrolein-mediated injury in nervous system trauma and diseasesSodium channels and multiple sclerosis: roles in symptom production, damage and therapy.Dalfampridine: review of its efficacy in improving gait in patients with multiple sclerosis.Revisiting Notch in remyelination of multiple sclerosis lesionsSpectrin and ankyrin-based cytoskeletons at polarized domains in myelinated axons.The mouse F3/contactin glycoprotein: structural features, functional properties and developmental significance of its regulated expression.Signals to promote myelin formation and repair.Regulation of remyelination in multiple sclerosis.Changes at the nodal and perinodal axonal domains: a basis for multiple sclerosis pathology?Oligodendrocytes and the early multiple sclerosis lesion.To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis.The node of Ranvier in CNS pathologyOligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.Axonal transport deficits in multiple sclerosis: spiraling into the abyss.Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteinsAlterations of Caspr2 and Nav1.6 on myelinated axon damage in a rat model of chronic cerebral hypoperfusion.Cytoskeletal transition at the paranodes: the Achilles' heel of myelinated axons.Regulation and dysregulation of axon infrastructure by myelinating glia.Acrolein induces myelin damage in mammalian spinal cord.
P2860
Q26777940-426A9346-46D1-4E58-8121-8A11E19C72DDQ26801386-D9A2AE96-E5D9-4278-A030-7A41BB955D9EQ27009974-466C2D61-6A2B-4260-B764-C10A38DB9BF7Q28081607-1B16616D-9850-4DB9-8C43-FE0F41DC6371Q28591753-47D74A67-5DC9-428C-8D52-42AB2F327B52Q30502019-BC4A420A-A80F-4A08-A21F-44A9497FA3BBQ33292270-D86A57F4-525A-45FB-AF8F-D6958E671DD5Q33650497-FC93B127-AB50-4462-AD2F-129FD4B47DC9Q33656323-75354F23-8D72-4037-8082-09565EB38651Q33666278-02591C18-8383-411B-B680-C4A172CAC998Q33722493-887BFEE3-4BA9-4C8B-A351-4E0786F5BA49Q33726825-3CED24E2-58C7-4D5F-8753-9A474DC11FBBQ33772195-D82502CE-917E-4100-9744-5D8A05861343Q33803753-DF1C1096-40B7-489E-8430-0E06FE92C8C8Q34086651-21A43986-7035-40D6-9998-EDACE2E7A988Q35103843-70994748-6B06-477C-99BE-4F446682694FQ35510088-D84CCAE4-4DE5-4F63-BC73-C9CADD4DBB4EQ35648729-20CE0368-80A3-437A-9B35-02B1A50BC4DBQ35765701-876D6897-176C-4B32-8992-3436CD8981ACQ36228999-6901A127-E723-469A-A85B-971CBC8E667BQ36452743-775D932A-C103-4031-BAAB-62E4A82D9F06Q36771880-54D0E184-E939-424E-A541-8FFA6C74094DQ36873901-1BFB6013-15A8-4724-A6D4-43A8F096B878Q37036099-20187D7D-A04D-4506-A06E-AEFA8F635CA1Q37119558-DC6952A2-B9F4-45D4-8431-42CBE37515B9Q37446659-EB988D70-2925-4E13-B1B3-1055984223F0Q37734207-48784D99-4E85-4118-969D-B95DD863934EQ37858668-1C382851-D308-4861-AAB8-D3B091DCF4D6Q37973165-121C69CD-6735-419E-8939-D0616AAA0663Q38029278-88731FC1-6989-4B64-93A4-FAF4DF03E209Q38192844-214D6315-C02A-43C1-98FA-E08099763F0AQ38218918-21B2A2E0-D6C7-4AD9-B75F-07813EDDDE77Q38609231-40250958-BEF1-4BC8-A10C-9DF240DA68F5Q38653397-7A15CCE0-73E0-4316-8D67-83F4F2801815Q39186137-C563D7C1-A678-45E6-A3CE-BF967DF36CF6Q41825402-35336DE5-6FF5-4CBB-85D1-AC8ABA5EF7FBQ41861637-5DB549B2-515F-4E2C-BC60-B8C1A87636E4Q43089378-E67695B5-2EF4-49C3-8B46-99577E2FE743Q46614637-0B2BF496-38E2-49EC-A447-10CEB5B19910Q46641095-D751186F-065B-4C78-9ECA-CC8CA97D3194
P2860
Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Changes in the expression and ...... in chronic multiple sclerosis.
@ast
Changes in the expression and ...... in chronic multiple sclerosis.
@en
type
label
Changes in the expression and ...... in chronic multiple sclerosis.
@ast
Changes in the expression and ...... in chronic multiple sclerosis.
@en
prefLabel
Changes in the expression and ...... in chronic multiple sclerosis.
@ast
Changes in the expression and ...... in chronic multiple sclerosis.
@en
P356
P1433
P1476
Changes in the expression and ...... in chronic multiple sclerosis.
@en
P2093
Guus Wolswijk
Rawien Balesar
P304
P356
10.1093/BRAIN/AWG151
P407
P577
2003-04-22T00:00:00Z